Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,dividendsPaid,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 13, 2021) 4","Short Ratio (May 13, 2021) 4","Short % of Float (May 13, 2021) 4","Short % of Shares Outstanding (May 13, 2021) 4","Shares Short (prior month Apr 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,CYCCP,48049000,12497400,,,-4165000,,-3478000,1739000,-2566000,-4305000,-4305000,,,,,,-687000,0,4305000,2566000,140000,,-3478000,-3528000,418320000,3768000,48049000,398000,51817000,9000,228000,-369550000,-730000,47777000,2772000,-730000,1354000,50463000,2010000,871000,270000,-78000,17997000,-609000,18047000,14371000,18000,-3566000,9000,-50000,242000,-78000,47691000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-5.346988,8.32 - 10.75,7.91,8.02,0.0,13,10,finmb_125004,NasdaqCM,"Cyclacel Pharmaceuticals, Inc.",USD,192,600,-14400000,False,False,us_market,NCM,-3.419,5.324,9.754167,-1.4341669,-0.1470312,8.847391,-0.52739143,-0.059609823,15820230,1.5627347,15,America/New_York,EDT,8.32,1630440003,-0.47000027,7.5,10.75,8.32,1015,"Cyclacel Pharmaceuticals, Inc. ",2,REGULAR,0,3.4699998,0.7154639,4.85 - 11.17,-2.8500004,-0.25514776,4.85,11.17,1627776000,1589313600,1589313600,1589313600,1.22,,,11.17,4.85,9.75,8.85,192,600,12.5M,,7.67M,0.00%,0.00%,376,0.84,0.11%,,865,0.6,5.73%,,,9.93,,"Jul 31, 2021","Apr 14, 2021",1:12,"May 30, 2016","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.14%,-36.63%,,,,-4.76M,-12.49M,-14.68M,-3.42,,47.78M,5.17,996k,2.07,18.20,5.32,-8.69M,-5.92M,Value,07922,Healthcare,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",Berkeley Heights,908 517 7330,NJ,1609372800,United States,http://www.cyclacel.com,86400,200 Connell Drive,866 271 3466,Biotechnology,Suite 1500
t-1,CYCCP,33259000,12497400,,,-3182000,,-2804000,1753000,-1415000,-3168000,-3168000,,,,,,-378000,0,3168000,1415000,-14000,,-2804000,-6629000,400071000,3543000,33259000,866000,36802000,6000,66000,-366072000,-746000,33406000,2486000,-746000,1333000,35469000,1313000,514000,684000,-42000,11348000,835000,7623000,10276000,122000,-1152000,4000,-50000,129000,-42000,32983000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-5.346988,8.32 - 10.75,7.91,8.02,0.0,13,10,finmb_125004,NasdaqCM,"Cyclacel Pharmaceuticals, Inc.",USD,192,600,-14400000,False,False,us_market,NCM,-3.419,5.324,9.754167,-1.4341669,-0.1470312,8.847391,-0.52739143,-0.059609823,15820230,1.5627347,15,America/New_York,EDT,8.32,1630440003,-0.47000027,7.5,10.75,8.32,1015,"Cyclacel Pharmaceuticals, Inc. ",2,REGULAR,0,3.4699998,0.7154639,4.85 - 11.17,-2.8500004,-0.25514776,4.85,11.17,1627776000,1589313600,1589313600,1589313600,1.22,,,11.17,4.85,9.75,8.85,192,600,12.5M,,7.67M,0.00%,0.00%,376,0.84,0.11%,,865,0.6,5.73%,,,9.93,,"Jul 31, 2021","Apr 14, 2021",1:12,"May 30, 2016","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.14%,-36.63%,,,,-4.76M,-12.49M,-14.68M,-3.42,,47.78M,5.17,996k,2.07,18.20,5.32,-8.69M,-5.92M,Value,07922,Healthcare,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",Berkeley Heights,908 517 7330,NJ,1609372800,United States,http://www.cyclacel.com,86400,200 Connell Drive,866 271 3466,Biotechnology,Suite 1500
t-2,CYCCP,24438000,12497400,,,-2537000,,-2256000,1497000,-1075000,-2572000,-2572000,,,,,,-281000,0,2572000,1075000,35000,,-2256000,-2306000,388583000,2775000,24438000,475000,27213000,5000,140000,-363269000,-881000,23130000,1712000,-881000,1279000,25934000,2166000,455000,144000,-50000,-50000,-126000,7623000,-2212000,17000,-2129000,6000,-50000,102000,-50000,24222000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-5.346988,8.32 - 10.75,7.91,8.02,0.0,13,10,finmb_125004,NasdaqCM,"Cyclacel Pharmaceuticals, Inc.",USD,192,600,-14400000,False,False,us_market,NCM,-3.419,5.324,9.754167,-1.4341669,-0.1470312,8.847391,-0.52739143,-0.059609823,15820230,1.5627347,15,America/New_York,EDT,8.32,1630440003,-0.47000027,7.5,10.75,8.32,1015,"Cyclacel Pharmaceuticals, Inc. ",2,REGULAR,0,3.4699998,0.7154639,4.85 - 11.17,-2.8500004,-0.25514776,4.85,11.17,1627776000,1589313600,1589313600,1589313600,1.22,,,11.17,4.85,9.75,8.85,192,600,12.5M,,7.67M,0.00%,0.00%,376,0.84,0.11%,,865,0.6,5.73%,,,9.93,,"Jul 31, 2021","Apr 14, 2021",1:12,"May 30, 2016","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.14%,-36.63%,,,,-4.76M,-12.49M,-14.68M,-3.42,,47.78M,5.17,996k,2.07,18.20,5.32,-8.69M,-5.92M,Value,07922,Healthcare,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",Berkeley Heights,908 517 7330,NJ,1609372800,United States,http://www.cyclacel.com,86400,200 Connell Drive,866 271 3466,Biotechnology,Suite 1500
t-3,CYCCP,26578000,12497400,,,-2452000,,-2166000,1309000,-1163000,-2472000,-2472000,,,,,,-286000,0,2472000,1163000,20000,,-2166000,-2216000,388520000,2593000,26578000,408000,29171000,5000,104000,-361013000,-934000,25342000,1512000,-934000,1238000,27933000,1805000,342000,1000,-50000,18256000,289000,18307000,16419000,9000,-1846000,5000,-51000,25000,-50000,26421000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-5.346988,8.32 - 10.75,7.91,8.02,0.0,13,10,finmb_125004,NasdaqCM,"Cyclacel Pharmaceuticals, Inc.",USD,192,600,-14400000,False,False,us_market,NCM,-3.419,5.324,9.754167,-1.4341669,-0.1470312,8.847391,-0.52739143,-0.059609823,15820230,1.5627347,15,America/New_York,EDT,8.32,1630440003,-0.47000027,7.5,10.75,8.32,1015,"Cyclacel Pharmaceuticals, Inc. ",2,REGULAR,0,3.4699998,0.7154639,4.85 - 11.17,-2.8500004,-0.25514776,4.85,11.17,1627776000,1589313600,1589313600,1589313600,1.22,,,11.17,4.85,9.75,8.85,192,600,12.5M,,7.67M,0.00%,0.00%,376,0.84,0.11%,,865,0.6,5.73%,,,9.93,,"Jul 31, 2021","Apr 14, 2021",1:12,"May 30, 2016","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-24.14%,-36.63%,,,,-4.76M,-12.49M,-14.68M,-3.42,,47.78M,5.17,996k,2.07,18.20,5.32,-8.69M,-5.92M,Value,07922,Healthcare,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.",Berkeley Heights,908 517 7330,NJ,1609372800,United States,http://www.cyclacel.com,86400,200 Connell Drive,866 271 3466,Biotechnology,Suite 1500
